Philadelphia, PA, September 17, 2007 – Women and men appear to respond
differently to the same biochemical manipulation. Major depressive disorder
(MDD) is one of the most common mental disorders, and it is also one of the
most studied. It is already known that reduced serotonin transmission
contributes to the pathophysiology, or functional changes, associated with MDD
and most of today’s most popular antidepressants block the serotonin “uptake
site”, also known as the transporter, in the brain. It is also known that
people with MDD are frequently found to have impaired impulse control. A new
study being published in the September 15th issue of Biological Psychiatry
now reports on important sex and genetic differences in the way that men and
women react to reductions in serotonin function, specifically in terms of
their mood and impulsivity.
Using a technique in healthy participants called acute tryptophan depletion,
which decreases serotonin levels in the brain, Walderhaug and colleagues found
that men became more impulsive, but did not experience any mood changes in
response to the induced chemical changes. However, women in this study
reported a worsening of their mood and they became more cautious, a response
commonly associated with depression. The researchers also discovered that the
mood lowering effect in women was influenced by variation in the promotor
region of the serotonin transporter gene (5-HTTLPR).
One of the study’s authors, Dr. Espen Walderhaug, explains, “We were surprised
to find such a clear sex difference, as men and women normally experience the
same effect when the brain chemistry is changed… Although we have the same
serotonergic system in the brain, it is possible that men and women utilize
serotonin differently.”
These findings highlight the complexity of studying and treating these
disorders, as the interactive effects of gender and genetic coding impacted
the outcomes in the men and women when their serotonergic functions were
disrupted. Dr. Walderhaug comments that their study’s findings “might be
relevant in understanding why women show a higher prevalence of mood and
anxiety disorders compared to men, while men show a higher prevalence of
alcoholism, ADHD and impulse control disorders.” John H. Krystal, M.D.,
Editor of Biological Psychiatry and affiliated with both Yale University
School of Medicine and the VA Connecticut Healthcare System, adds that the
response patterns that have emerged in these findings are “the beginnings of
an understanding for these sex-related effects.” Ultimately, it is hoped that
these findings further advance the ability to quickly and more accurately
treat patients.
# # #
Notes to Editors:
The article is “Interactive Effects of Sex
and 5-HTTLPR on Mood and Impulsivity During Tryptophan Depletion in Healthy
People” by Espen Walderhaug, Andres Magnusson, Alexander Neumeister, Jaakko
Lappalainen, Hilde Lunde, Helge Refsum and Nils Inge Landrø. Drs. Walderhaug
and Landrø are with the Department of Psychology at the University of Oslo in
Oslo, Norway. Dr. Magnusson is affiliated with National University Hospital
in Reykjavik, Iceland. Drs. Neumeister and Lappalainen are with Yale
University School of Medicine in West Haven, Connecticut. Drs. Lunde and
Refsum are affiliated with the Department of Psychopharmacology at
Diakonhjemmet University Hospital, Oslo, Norway. The article appears in
Biological Psychiatry, Volume 62, Issue 6 (September 15, 2007), published
by Elsevier.
Full text of the article mentioned above is available upon request. Contact
Jayne M. Dawkins at (215) 239-3674 or ja.dawkins@elsevier.com
to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international
rapid-publication journal is the official journal of the Society of Biological
Psychiatry. It covers a broad range of topics in psychiatric neuroscience and
therapeutics. Both basic and clinical contributions are encouraged from all
disciplines and research areas relevant to the pathophysiology and treatment
of major neuropsychiatric disorders. Full-length and Brief Reports of novel
results, Commentaries, Case Studies of unusual significance, and
Correspondence and Comments judged to be of high impact to the field are
published, particularly those addressing genetic and environmental risk
factors, neural circuitry and neurochemistry, and important new therapeutic
approaches. Concise Reviews and Editorials that focus on topics of current
research and interest are also published rapidly.
Biological Psychiatry (www.sobp.org/journal)
is ranked 4th out of the 95 Psychiatry titles and 16th out of 199
Neurosciences titles on the 2006 ISI Journal Citations Reports® published by
Thomson Scientific.
About Elsevier
Elsevier is a world-leading publisher of
scientific, technical and medical information products and services. Working
in partnership with the global science and health communities, Elsevier’s
7,000 employees in over 70 offices worldwide publish more than 2,000 journals
and 1,900 new books per year, in addition to offering a suite of innovative
electronic products, such as ScienceDirect,
MD Consult, Scopus,
bibliographic databases, and online reference works.
Elsevier is a global business
headquartered in Amsterdam, The Netherlands and has offices worldwide.
Elsevier is part of Reed Elsevier Group
plc, a world-leading publisher and information provider. Operating in the
science and medical, legal, education and business-to-business sectors, Reed
Elsevier provides high-quality and flexible information solutions to users,
with increasing emphasis on the Internet as a means of delivery. Reed
Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock
Exchange), RUK and ENL (New York Stock Exchange).
Media contact:
Jayne M. Dawkins
Strategic Marketing
Manager - Elsevier
+1 215-239-3674
ja.dawkins@elsevier.com